EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

被引：0
|
作者：
Martin, M. [1 ]
Eiermann, W. [2 ]
Rugo, H. S. [3 ]
Ettl, J. [4 ]
Hurvitz, S. A. [5 ]
Goncalves, A. [6 ]
Yerushalmi, R. [7 ]
Markova, D. [8 ]
Tudor, I. C. [8 ]
Blum, J. L. [9 ]
Hannah, A. L. [10 ]
Litton, J. K. [11 ]
机构：
[1] Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Med Oncol, CIBERONC,GEICAM, Madrid, Spain
[2] Interdisziplinares Onkol Zentrum Munchen, Chest Surg, Munich, Germany
[3] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA
[4] Tech Univ Munich, Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany
[5] Univ Calif Los Angeles, Hematol Oncol, Los Angeles, CA USA
[6] Inst Paoli Calmettes, Med Oncol, Marseille, France
[7] Beilinson Med Ctr, Rabin Med Ctr, Med Oncol, Petah Tiqwa, Israel
[8] Pfizer Inc, Biostat, San Francisco, CA USA
[9] Baylor Sammons Canc Ctr, Med Oncol, Dallas, TX USA
[10] Pfizer Inc, Med Oncol, San Francisco, CA USA
[11] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
303P
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [21] Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial
    Ettl, J.
    Quek, R. G. W.
    Lee, K. -H.
    Rugo, H. S.
    Hurvitz, S.
    Goncalves, A.
    Fehrenbacher, L.
    Yerushalmi, R.
    Mina, L. A.
    Martin, M.
    Roche, H.
    Im, Y. -H.
    Markova, D.
    Bhattacharyya, H.
    Hannah, A. L.
    Eiermann, W.
    Blum, J. L.
    Litton, J. K.
    ANNALS OF ONCOLOGY, 2018, 29 (09) : 1939 - 1947
  • [22] Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial
    Hurvitz, S. A.
    Rugo, H. S.
    Ettl, J.
    Martin, M.
    Roche, H.
    Lee, K-H.
    Goodwin, A.
    Usari, T.
    Lanzalone, S.
    Guenzel, C. A.
    Blum, J.
    Litton, J. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S482 - S482
  • [23] Patient-reported outcomes in patients with HER2-advanced breast cancer and a germline BRCA1/2 mutation receiving talazoparib vs physician's choice of chemotherapy: A focus on EMBRACA ECOG performance status subgroups
    Rugo, Hope S.
    Quek, Ruben G. W.
    Bhattacharyya, Helen
    Goncalves, Anthony
    Ettl, Johannes
    Hurvitz, Sara A.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial
    Fasching, P. A.
    Quek, R. G. W.
    Bhattacharyya, H.
    Hurvitz, S. A.
    Rugo, H. S.
    Ettl, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2-) advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA1/2) mutation
    Litton, Jennifer K.
    Laird, A. Douglas
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Martin, Miguel
    Roche, Henri
    Im, Young-Hyuck
    Goodwin, Annabel
    Blum, Joanne L.
    Eiermann, Wolfgang
    Chen, Ying
    Lanzalone, Silvana
    Chelliserry, Jijumon
    Czibere, Akos
    Albacker, Lee A.
    Frampton, Garrett M.
    Mina, Lida A.
    CANCER RESEARCH, 2020, 80 (16)
  • [26] Awareness and availability of routine germline BRCA1/2 (gBRCA1/2) mutation testing in patients (pts) with advanced breast cancer (ABC) in Germany
    Lux, M. P.
    Decker, T.
    Runkel, E. D.
    Niyazov, A.
    Quek, R. G. W.
    Glastetter, E.
    Marschner, N. W.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S75 - S76
  • [27] Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
    Domchek, Susan M.
    Aghajanian, Carol
    Shapira-Frommer, Ronnie
    Schmutzler, Rita K.
    Audeh, M. William
    Friedlander, Michael
    Balmana, Judith
    Mitchell, Gillian
    Fried, Georgeta
    Stemmer, Salomon M.
    Hubert, Ayala
    Rosengarten, Ora
    Loman, Niklas
    Robertson, Jane D.
    Mann, Helen
    Kaufman, Bella
    GYNECOLOGIC ONCOLOGY, 2016, 140 (02) : 199 - 203
  • [28] Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).
    Meisner, Eleanor
    Rollins, Rebecca
    Ensor, Joe
    Moran, Amber
    Woodward, Amanda
    Ahn, Eugene R.
    Lynch, Cynthia Anne
    Citrin, Dennis L.
    Hansra, Damien
    Aithal, Sramila S.
    Ninan, Mary
    Nixon, Daniel W.
    Zook, Susan
    Ali, Siraj Mahamed
    Markman, Maurie
    Alvarez, Ricardo H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
    Lee, Kyung-Hun
    Sohn, Joohyuk
    Goodwin, Annabel
    Usari, Tiziana
    Lanzalone, Silvana
    Im, Seock-Ah
    Kim, Sung-Bae
    CANCER RESEARCH AND TREATMENT, 2021, 53 (04): : 1084 - 1095
  • [30] A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
    Turner, Nicholas C.
    Telli, Melinda L.
    Rugo, Hope S.
    Mailliez, Audrey
    Ettl, Johannes
    Grischke, Eva-Maria
    Mina, Lida A.
    Balmana, Judith
    Fasching, Peter A.
    Hurvitz, Sara A.
    Wardley, Andrew M.
    Chappey, Colombe
    Hannah, Alison L.
    Robson, Mark E.
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2717 - 2724
12345